INCREASED TUMORIGENICITY IN THE HUMAN PANCREATIC-CELL LINE MIA PACA-2IS ASSOCIATED WITH AN ABERRANT REGULATION OF AN IGF-1 AUTOCRINE LOOP AND LACK OF EXPRESSION OF THE TGF-BETA TYPE RII RECEPTOR
Jw. Freeman et al., INCREASED TUMORIGENICITY IN THE HUMAN PANCREATIC-CELL LINE MIA PACA-2IS ASSOCIATED WITH AN ABERRANT REGULATION OF AN IGF-1 AUTOCRINE LOOP AND LACK OF EXPRESSION OF THE TGF-BETA TYPE RII RECEPTOR, Journal of cellular physiology, 165(1), 1995, pp. 155-163
The growth characteristics associated with tumorigenicity were determi
ned in clones of MIA PaCa-2 and PANC-1 pancreatic carcinoma cells. MIA
PaCa-2 cells differed from PANC-1 cells in that they rapidly formed t
umors in nude mice, formed colonies more rapidly and formed larger col
onies in soft agar, and were cloned more efficiently when seeded at lo
w density. MIA PaCa-2 cells but not PANC-1 cells were stimulated to es
cape quiescence and undergo DNA synthesis with nutrient media lacking
growth factors. Both cell lines were stimulated to proliferate with se
rum-free media containing EGF, transferrin, and insulin. Antibody neut
ralization assays indicated that an IGF-1 autocrine loop was required
for the nutrient stimulation of growth in MIA PaCa-2 cells and for the
growth-factor stimulation in both MIA PaCa-2 and PANC-1 cells. Both c
ell lines were stimulated to proliferate with exogenous IGF-1 in basal
media; this stimulation was specifically blocked by antibodies to IGF
-1 or its receptor. MIA PaCa-2 and PANC-1 cells expressed similar leve
ls of IGF-1 receptor mRNA and showed similar binding kinetics in recep
tor binding assays. In contrast to PANC-1 cells, MIA PaCa-2 cells were
insensitive to TGF-beta 1 and did not express TGF-beta receptor type
II. The results suggest that the growth-factor independence is represe
ntative of a more tumorigenic phenotype. We hypothesize that growth-fa
ctor independence of MIA PaCa-2 cells is mediated by an aberrant regul
ation of an IGF-1 autocrine loop. A decreased regulation of this IGF-1
loop may be potentiated by loss of response to TGF-beta. (C) 1995 Wil
ey-Liss, Inc.